SERA Overview

Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Wall Street analysts forecast SERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SERA is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sera Prognostics Inc revenue for the last quarter amounts to 10.00K USD, decreased -58.33

Sera Prognostics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -36.00

Sera Prognostics Inc (SERA) has 71 emplpoyees as of March 26 2026.

Today SERA has the market capitalization of 79.46M USD.